Blood Thinner Cuts Stroke Recurrence Across Brain Patterns
Stroke and TIA survivors saw fewer repeat strokes on asundexian without added major bleeding in a MRI substudy.
Updated on Nov. 3, 2026 in Stroke
Live Poll
Would you feel comfortable taking a new stroke-prevention pill if it lowered stroke risk without more bleeding?
Bayer's experimental blood thinner asundexian reduced the recurrence of ischemic stroke without raising major bleeding, regardless of the pattern of brain injury seen on baseline MRI, according to a substudy of the phase 3 OCEANIC-STROKE trial presented at the World Stroke Congress 2026 in Seoul, South Korea. The findings are most relevant to people who have had a noncardioembolic ischemic stroke or transient ischemic attack and are considering antiplatelet-based prevention.
Why it matters
Stroke survivors face a high risk of another stroke, and current prevention relies on antiplatelet medicines that carry their own bleeding trade-offs. The substudy was designed to see whether patient characteristics seen on imaging, such as infarct pattern, change how well a treatment works, which could help future care be better matched to individual patients.
The OCEANIC-STROKE trial randomized 12,327 patients with noncardioembolic ischemic stroke or TIA, 6,162 to asundexian and 6,165 to placebo, over 19 months of follow-up. This MRI substudy analyzed patients by baseline infarct pattern and found ischemic stroke in 8.2% of asundexian patients versus 12.1% of placebo patients, a result that did not show a statistically significant interaction with infarct pattern.
The players
Bayer
A global pharmaceutical company developing asundexian, an investigational factor XIa inhibitor for preventing stroke.
Raed Joundi
A researcher at McMaster University who presented the OCEANIC-STROKE MRI substudy at the World Stroke Congress 2026.
The details
Asundexian is an investigational oral medicine that targets factor XIa, a clotting protein involved in forming the kind of blood clots that can cause stroke, and it is being tested alongside standard antiplatelet therapy. The substudy grouped patients by what their baseline MRI showed, including subcortical infarcts of 15 mm or greater, which affected 512 patients, and cortical infarcts, seen in 544 patients. Eligible patients had a nonlacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging, and the analysis asked whether these imaging features changed how well the drug worked.
Timeline
Presented October 21-23, 2026, at the World Stroke Congress 2026 in Seoul, South Korea.
Patients were followed for 19 months to measure stroke incidence in the full OCEANIC-STROKE trial.
Health Landscape
Antiplatelet therapy remains the standard approach to preventing recurrent stroke after a noncardioembolic event, and newer anticoagulant candidates like asundexian are being evaluated as possible additions. This substudy adds to the effort to identify which patients benefit most by linking treatment response to imaging-defined infarct patterns.
If you have had a stroke or TIA, this research is worth raising with your neurologist or primary care doctor as the evidence on newer prevention options develops. Asundexian is not yet an approved treatment, so no change to your current medication should be made based on this study alone.
The takeaway
The main insight is that asundexian's stroke-prevention benefit appeared consistent across different patterns of brain injury seen on MRI, which is a useful step toward matching treatments to patients. If you have had a stroke or TIA, ask your doctor whether your own brain-imaging findings should factor into your secondary prevention plan.
Further reading
For broader context on how stroke prevention is evolving, explore our Stroke coverage.
More information
Review the OCEANIC-STROKE ClinicalTrials.gov registry record for the trial's official study details.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you feel comfortable taking a new stroke-prevention pill if it lowered stroke risk without more bleeding?
